Our Idea

The Problem

Traditional e-prescribing cannot accommodate specialty orders, these medications often require durable medical equipment and ancillary supplies, patient signoff, prior authorizations, monthly lab tests and other processes unique to the specialty space. Ordering specialty medications and exchanging information is not currently automated resulting in a fragmented, error-prone and inefficient system that relies on paper forms, faxes and phone calls.

The Solution

ZappRx revolutionizes the way specialty medications are managed, from order initiation to therapy administration. Engaging each stakeholder via a secure and collaborative online platform enables patients, physicians and pharmacists to input, update, submit and confirm specialty prescription information, allowing patients to obtain their medications faster and get back to life.

Recent Press

Our Investors

Atlas Ventures

Atlas Venture invests in the earliest stages of technology and life sciences innovation. We take pride in partnering with enterpreneurs solving difficult problems in new markers.
Read More

Sr One

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
Read More

Latest Tweets


  • Specialty drugs typically require special handling and administration, sometimes unique inventory management and most often more knowledge and time from all professionals involved prior to dispensing.

    Jean-Fran├žois Formela - Atlas Venture
  • The ZappRx patient-centric platform is uniquely fitted to create value throughout the process of getting these high impact medications to patients from prescribing to dispensing. The application can be accessed in real time by all constituents involved and will bring efficiency to this complex process resulting in better access, compliance and outcome.

    Jean-Fran├žois Formela - Atlas Ventures